Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center

Click to increase image sizeClick to decrease image size

Acknowledgements

We would like to express our sincere gratitude to all the patients who entrusted us with their care. We also would like to extend our appreciation to the healthcare professionals at The University of Texas MD Anderson Cancer Center for their dedication and expertise, facilitating this research.

Authorship statement

JZ and CG conducted the research and wrote the original manuscript draft. All authors reviewed and edited the manuscript. FY carried out statistical analyses. CYO conducted research and analyses related to pathology. SW, BD, JG, PF, and CP conducted research and analyses related to radiation oncology. WC, PJ, and OO provided support for the research and contributed to the interpretation of the results. MW and CG were responsible for conceptualization and supervised the study.

Disclosure statement

Charles Gaulin:

Honoraria: DeciBio, ADC Therapeutics, Sanofi.

Michael Wang:

Consultancy: AbbVie, Acerta Pharma, ADC Therapeutics America, Amphista Therapeutics Limited, AstraZeneca, BeiGene, bE Biopharma, BioInvent, Bristol Myers Squibb, Deciphera, Genentech, InnoCare, Janssen, Kite Pharma, Lilly, Merck, Miltenyi Biomedicine, Oncternal, Parexel, Pepromene Bio, Pharmacyclics.

Research: Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, Vincerx.

Honoraria: AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Bristol Myers Squibb, CAHON, Catamount Medical Education, Dava Oncology, Genmab, Janssen, Kite Pharma, MJH Life Sciences, Merck, MSC National Research Institute of Oncology, Nurix, Pharmacyclics, Physicians Education Resources (PER), Research to Practice, Scripps, Studio ER Congressi, South African Clinical Hematology Society, WebMD.

Institutional review board statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (protocol 2023-0936, approved on November 17, 2023).

Informed consent statement

Informed consent was obtained from all subjects involved in the study.

Data availability statement

Anonymized data supporting the findings of this study, including clinical details and outcomes, are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions but will be provided in a manner that upholds the anonymity and confidentiality of the patients involved in accordance with institutional guidelines.

Additional information

Funding

This research received no external funding.